Evaluation of hypoxia in a feline model of head and neck cancer using 64Cu-ATSM positron emission tomography/computed tomography

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Ballegeer, Elizabeth A ^a   Madrill, Nicole J ^a   Berger, Kevin L ^b   Agnew, Dalen W ^a   McNiel, Elizabeth A ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Chesapeake Medical Imaging   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

64Cu ATSM PET CT; Feline; Head and neck cancer; Hypoxia; O2 probe; Pimonidazole

Indexed keywords

ANGINEX; COPPER 64; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PIMONIDAZOLE; TOCERANIB; UNCLASSIFIED DRUG; COPPER; COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); ORGANOMETALLIC COMPOUND; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; FEMALE; GOITER; HEAD AND NECK CANCER; HYPERTHYROIDISM; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OSTEOSARCOMA; OTITIS MEDIA; OXYGENATION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; THYROID ADENOMA; TREATMENT RESPONSE; TUMOR HYPOXIA; TUMOR VOLUME; ANIMAL; ANOXIA; CAT; DIAGNOSTIC USE; DISEASE MODEL; HEAD AND NECK TUMOR; MULTIMODAL IMAGING; PROCEDURES; SCINTISCANNING;

ANIMALS; ANOXIA; CARCINOMA, SQUAMOUS CELL; CATS; COPPER RADIOISOTOPES; DISEASE MODELS, ANIMAL; FEMALE; HEAD AND NECK NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; MULTIMODAL IMAGING; ORGANOMETALLIC COMPOUNDS; THIOSEMICARBAZONES;

EID: 84876785347     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-218     Document Type: Article

References (68)

1. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62. 10.1126/science.1104819, 15637262.
2. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004, 14(3):198-206. 10.1016/j.semradonc.2004.04.008, 15254862.
3. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427(6976):695. 10.1038/427695a, 14973470.
4. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239. 10.1007/s10555-007-9055-1, 17440684.
5. Hall EJ, Giaccia AJ. Oxygen effec and re-oxygenation. Radiobiology for the Radiologist 2012, Philadelphia: Lipponcott, Williams & Wilkins, Hall EJ, Giaccia AJ, 7.
6. Eckert AW, Lautner MH, Schutze A, Taubert H, Schubert J, Bilkenroth U. Coexpression of hypoxia-inducible factor-1alpha and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology 2011, 58(7):1136-1147. 10.1111/j.1365-2559.2011.03806.x, 21438910.
7. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26(1):45-50. 10.1016/0167-8140(93)90025-4, 8438086.
8. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Rey JM, Garcia-Garcia A. Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett 2010, 295(2):135-143. 10.1016/j.canlet.2010.03.019, 20418015.
9. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer Lett 2011, 313(1):1-8. 10.1016/j.canlet.2011.08.017, 21959110.
10. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22(21):3213-3220. 10.1038/sj.onc.1206385, 12761491.
11. Roh JL, Cho KJ, Kwon GY, Ryu CH, Chang HW, Choi SH, Nam SY, Kim SY. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 2009, 45(1):63-68. 10.1016/j.oraloncology.2008.03.017, 18620902.
12. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997, 38(2):285-289. 10.1016/S0360-3016(97)00101-6, 9226314.
13. Bowen SR, van der Kogel AJ, Nordsmark M, Bentzen SM, Jeraj R. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol 2011, 38(6):771-780. 10.1016/j.nucmedbio.2011.02.002, 3157049, 21843774.
14. Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y, Yamazaki H, Naito Y, Senda M. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 2011, 25(9):625-633. 10.1007/s12149-011-0508-9, 21720778.
15. Maftei CA, Shi K, Bayer C, Astner ST, Vaupel P. Comparison of (immuno-)fluorescence data with serial [(1)(8)F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers. Radiother Oncol 2011, 99(3):412-417. 10.1016/j.radonc.2011.05.079, 21719136.
16. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, pOo2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61(5):1493-1502. 10.1016/j.ijrobp.2004.12.057, 15817355.
17. Yamada T, Uchida M, Kwang-Lee K, Kitamura N, Yoshimura T, Sasabe E, Yamamoto T. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2012, 113(4):464-471.
18. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011, 100(1):22-32. 10.1016/j.radonc.2011.03.004, 21511351.
19. Liptak JM, Withrow SJ. Oral tumors. Withrow and MacEwen's Small Animal Clinical Oncology. Volume 4th 2007, 455-510. St. Louis: Saunders Elsevier Inc, Withrow SJ, Vail DM.
20. Dorn CR, Priester WA. Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. J Am Vet Med Assoc 1976, 169(11):1202-1206.
21. Bertone ER, Snyder LA, Moore AS. Environmental and lifestyle risk factors for oral squamous cell carcinoma in domestic cats. J Vet Intern Med 2003, 17(4):557-562. 10.1111/j.1939-1676.2003.tb02478.x, 12892308.
22. McNiel EA, Carmella SG, Heath LA, Bliss RL, Le KA, Hecht SS. Urinary biomarkers to assess exposure of cats to environmental tobacco smoke. Am J Vet Res 2007, 68(4):349-353. 10.2460/ajvr.68.4.349, 17397288.
23. Snyder LA, Bertone ER, Jakowski RM, Dooner MS, Jennings-Ritchie J, Moore AS. p53 expression and environmental tobacco smoke exposure in feline oral squamous cell carcinoma. Vet Pathol 2004, 41(3):209-214. 10.1354/vp.41-3-209, 15133168.
24. Looper JS, Malarkey DE, Ruslander D, Proulx D, Thrall DE. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. Vet Comp Oncol 2006, 4(1):33-40. 10.1111/j.1476-5810.2006.00091.x, 19754827.
25. Sabattini S, Marconato L, Zoff A, Morini M, Scarpa F, Capitani O, Bettini G. Epidermal growth factor receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. J Feline Med Surg 2010, 12(10):760-768. 10.1016/j.jfms.2010.04.010, 20674427.
26. Beam SL, Rassnick KM, Moore AS, McDonough SP. An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Vet Pathol 2003, 40(5):496-500. 10.1354/vp.40-5-496, 12949405.
27. Hayes A, Scase T, Miller J, Murphy S, Sparkes A, Adams V. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. J Comp Pathol 2006, 135(2-3):93-99.
28. DiBernardi L, Dore M, Davis JA, Owens JG, Mohammed SI, Guptill CF, Knapp DW. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fat Acids 2007, 76(4):245-250.
29. Dewhirst MW, Klitzman B, Braun RD, Brizel DM, Haroon ZA, Secomb TW. Review of methods used to study oxygen transport at the microcirculatory level. Int J Cancer 2000, 90(5):237-255. 10.1002/1097-0215(20001020)90:5<237::AID-IJC1>3.0.CO;2-T, 11091348.
30. Bruehlmeier M, Kaser-Hotz B, Achermann R, Bley CR, Wergin M, Schubiger PA, Ametamey SM. Measurement of tumor hypoxia in spontaneous canine sarcomas. Vet Radiol Ultrasound 2005, 46(4):348-354. 10.1111/j.1740-8261.2005.00065.x, 16229439.
31. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004, 6(5):291-305. 10.1016/j.mibio.2004.06.007, 15380739.
32. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006, 47(6):989-998.
33. Azuma C, Raleigh JA, Thrall DE. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat Res 1997, 148(1):35-42. 10.2307/3579536, 9216616.
34. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DY, Chou SC, Raleigh JA. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int J Radiat Oncol Biol Phys 2006, 64(2):592-602. 10.1016/j.ijrobp.2005.09.010, 16289910.
35. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 2001, 49(2):569-574. 10.1016/S0360-3016(00)01505-4, 11173156.
36. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001, 354(Pt 2):233-242. 1221648, 11171099.
37. Kubota K, Matsuzawa T, Ito M, Ito K, Fujiwara T, Abe Y, Yoshioka S, Fukuda H, Hatazawa J, Iwata R. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med 1985, 26(1):37-42.
38. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
39. Hall EJ, Giaccia AJ. Oxygen effect and reoxygenation. Radiobiology for the Radiologist. Volume 7th 2012, 86-103. Philadephia: Lippincott, Williams & Wilkins, Hall EJ, Giacca AJ.
40. Kawakami K, Hattori M, Inoue T, Maruyama Y, Ohkanda J, Kato N, Tongu M, Yamada T, Akimoto M, Takenaga K. A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits growth in xenografts. Anti Cancer Agents Med Chem 2012, 17(7):791-800.
41. Citrin D, Camphausen K. Advancement of antiangiogenic and vascular disrupting agents combined with radiation. Radiation Oncology Advances 2008, 153-172. New York: Springer, LLC, Bentzen SM, Harari PM, Tome WA, Mehta MP.
42. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82(10):699-757. 10.1080/09553000601002324, 17118889.
43. Smith LP, Thomas GR. Animal models for the study of squamous cell carcinoma of the upper aerodigestive tract: a historical perspective with review of their utility and limitations. Part A. Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of transplanted xenogeneic human tumors. Int J Cancer 2006, 118(9):2111-2122. 10.1002/ijc.21694, 16380986.
44. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007, 17(4):861-872. 10.1007/s00330-006-0431-y, 1820761, 17043737.
45. Wood KA, Wong WL, Saunders MI. [(64)Cu]diacetyl-bis(N(4)-methyl-thiosemicarbazone)-a radiotracer for tumor hypoxia. Nucl Med Biol 2008, 35(4):393-400. 10.1016/j.nucmedbio.2008.02.002, 18482676.
46. Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Mori T, Yoshii H, Asai T, Okazawa H, Welch MJ, Fujibayashi Y. Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol 2011, 38(2):151-157. 10.1016/j.nucmedbio.2010.08.009, 21315269.
47. Weeks AJ, Paul RL, Marsden PK, Blower PJ, Lloyd DR. Radiobiological effects of hypoxia-dependent uptake of 64Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells. Eur J Nucl Med Mol Imaging 2010, 37(2):330-338. 10.1007/s00259-009-1305-8, 19915836.
48. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007, 43:4893-4902.
49. de Lussanet QG, Beets-Tan RG, Backes WH, van der Schaft DW, van Engelshoven JM, Mayo KH, Griffioen AW, Beets-Tan RGH, van der Schaft DWJ, van Engelshoven JMA. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. Eur J Cancer 2004, 40(8):1262-1268. 10.1016/j.ejca.2004.01.020, 15110892.
50. Black NF, McJames S, Rust TC, Kadrmas DJ. Evaluation of rapid dual-tracer (62)Cu-PTSM + (62)Cu-ATSM PET in dogs with spontaneously occurring tumors. Phys Med Biol 2008, 53(1):217-232. 10.1088/0031-9155/53/1/015, 18182698.
51. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008, 51(11):1641-1648. 10.1007/s10350-008-9420-3, 18682881.
52. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001, 42(4):655-661.
53. Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, Omura M, Odagiri K, Tohnai I, Inoue T. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011, 25(5):339-345. 10.1007/s12149-011-0471-5, 21327756.
54. Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl Med Biol 2011, 38(7):945-951. 10.1016/j.nucmedbio.2011.02.016, 21982566.
55. Skovgaard D, Kjaer M, Madsen J, Kjaer A. Noninvasive 64Cu-ATSM and PET/CT assessment of hypoxia in rat skeletal muscles and tendons during muscle contractions. J Nucl Med 2009, 50(6):950-958. 10.2967/jnumed.109.062216, 19443591.
56. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55(5):1233-1238. 10.1016/S0360-3016(02)04477-2, 12654432.
57. Nathan SS, DiResta GR, Casas-Ganem JE, Hoang BH, Sowers R, Yang R, Huvos AG, Gorlick R, Healey JH. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 2005, 11(6):2389-2397. 10.1158/1078-0432.CCR-04-2048, 15788690.
58. Nathan SS, Huvos AG, Casas-Ganem JE, Yang R, Linkov I, Sowers R, DiResta GR, Gorlick R, Healey JH. Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. Ann Acad Med Singap 2009, 38(12):1041-1047.
59. Zachos TA, Aiken SW, DiResta GR, Healey JH. Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors. Clin Orthop Relat Res 2001, 385:230-236.
60. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30(6):844-850. 10.1007/s00259-003-1130-4, 12692685.
61. Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, Stanzel S, Hamacher K, Coenen HH, Westhofen M. pO(2) polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004, 180(10):616-622. 10.1007/s00066-004-1229-y, 15480509.
62. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging 2009, 36(10):1565-1573. 10.1007/s00259-009-1154-5, 19430784.
63. Cheeseman MT, Tyrer HE, Williams D, Hough TA, Pathak P, Romero MR, Hilton H, Bali S, Parker A, Vizor L. HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants. PLoS Genet 2011, 7(10):e1002336. 10.1371/journal.pgen.1002336, 3197687, 22028672.
64. Peterson ME. Hyperthyroidism. Textbook of Veterinary Internal Medicine 2000, 1400-1419. Philadelphia: W.B. Saunders, Ettinger SJ, Feldman EC.
65. Itoh A, Iwase K, Jimbo S, Yamamoto H, Yamamoto N, Kokubo M, Senda T, Nakai A, Nagagasaka A, Nagasaka T. Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World J Surg 2010, 34(2):242-248. 10.1007/s00268-009-0344-4, 20041248.
66. Zhong Z, Li X, Yamashina S, von Frankenberg M, Enomoto N, Ikejima K, Kolinsky M, Raleigh JA, Thurman RG. Cyclosporin A causes a hypermetabolic state and hypoxia in the liver: prevention by dietary glycine. J Pharmacol Exp Ther 2001, 299(3):858-865.
67. Cook GJ, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998, 39(1):99-103.
68. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ, Dings RPM, Loren M, Heun H. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007, 13(11):3395-3402. 10.1158/1078-0432.CCR-06-2441, 2914684, 17545548.